Use of SWELL1 inhibitors and modulators to treat type 2 diabetes and obesity
The invention provides the use of SWELL1 inhibitors and modulators for therapeutic use, e.g., to treat obesity and type 2 diabetes.
1. A method for treating type 2 diabetes in a human patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of a SWELL1 modulator, wherein the SWELL1 modulator is a compound of formula I:
wherein:
X 1a and X 2a are independently halogen;
R 1a is C 1-6 alkyl, 3-6 membered cycloalkyl, or phenyl, wherein the C 1-6 alkyl is optionally substituted with 3-6 membered cycloalkyl;
R 2a is hydrogen or C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted with carboxy; and
R 3a is C 1-6 alkyl;
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the SWELL1 modulator is DCPIB.
3. The method of claim 1 , wherein the administering to the patient of the SWELL1 modulator is sufficient to upregulate the expression of SWELL1, or alter expression of a SWELL1 associated protein.
4. The method of claim 1 , wherein the administering to the patient of the SWELL1 modulator is sufficient to upregulate the expression of SWELL1.
5. The method of claim 3 , wherein the SWELL1 associated protein is LRRC8b,c,d,e, GRB2, Cav1, IRS1, or IRS2.
6. The method of claim 1 , wherein the administering to the patient of the therapeutically effective amount of the SWELL1 modulator increases the patient's insulin sensitivity.
7. The method of claim 1 , wherein the administering to the patient of the therapeutically effective amount of the SWELL1 modulator increases the patient's insulin secretion.